Biological
VAC-3S
VAC-3S is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed133%
unknown267%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_1
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
NCT02390466
unknownphase_2
Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection
NCT02041247
completedphase_1
Phase I/IIa Dose-escalation Clinical Study of VAC-3S
NCT01549119
Clinical Trials (3)
Showing 3 of 3 trials
NCT02390466Phase 1
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
NCT02041247Phase 2
Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection
NCT01549119Phase 1
Phase I/IIa Dose-escalation Clinical Study of VAC-3S
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3